{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:33:12Z","timestamp":1770823992609,"version":"3.50.1"},"reference-count":62,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,12]],"date-time":"2006-01-12T00:00:00Z","timestamp":1137024000000},"content-version":"vor","delay-in-days":407,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Efforts made during the last few years have helped unravel the complex pathogenesis of the myelodysplastic syndromes (MDS). A large number of studies, made possible by the introduction of newer technologies, have led to major progress in understanding the heterogeneous genetic and biological abnormalities contributing to the development and progression of myelodysplasia. better insights into these pathogenetic processes will aid the development of newer and more successful therapies for MDS patients. The identification of specific genes involved in the emergence and progression of the myelodysplastic clone has extended biological findings into the clinic. Recently, several clinical trials have used selective compounds to target and inhibit the disrupted signal transduction pathway in myelodysplastic patients. The demonstration of genetic abnormalities present not only in MDS patients but also in acute myeloid leukemia (AML) patients or in chronic myeloproliferative disorders (CMPD) has prompted extension of a number of clinical trials from AML and CMPD to MDS patients. In spite of this, the more complex and heterogeneous pathogenesis underlying the myelodysplastic process is responsible for the often different and in same cases worse clinical results obtained in MDS patients. Finally, the identification of myelodysplasia\u2010associated antigens that may be targeted by an immunotherapeutic approach represents a future perspective in tailored therapy for MDS patients.<\/jats:p>","DOI":"10.1196\/annals.1322.048","type":"journal-article","created":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T20:08:46Z","timestamp":1105646926000},"page":"400-408","source":"Crossref","is-referenced-by-count":8,"title":["Myelodysplastic Syndromes"],"prefix":"10.1111","volume":"1028","author":[{"given":"DANIELA","family":"CILLONI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FRANCESCA","family":"MESSA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SONIA","family":"CARTURAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FRANCESCA","family":"ARRUGA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ILARIA","family":"DEFILIPPI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EMANUELA","family":"MESSA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ENRICO","family":"GOTTARDI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GIUSEPPE","family":"SAGLIO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402107"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30326-5"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90641-B"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(89)90021-6"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(92)90097-Q"},{"key":"e_1_2_5_7_2","first-page":"10","article-title":"Dissecting oncogenes and tyrosines kinases in AML cells","volume":"21","author":"Bianchi E.","year":"2003","journal-title":"Med. Gen. Med"},{"key":"e_1_2_5_8_2","first-page":"339","article-title":"Genetics lesions in preleukemia","volume":"3","author":"Carter G.","year":"1992","journal-title":"Crit. Rev. Oncogenet"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509051705"},{"key":"e_1_2_5_10_2","unstructured":"Le Beau M.M.et al.2001. Cytogenetics of myelodysplastic syndromes. Best Pract. Res. Clin. Haematol. 14479\u201314495."},{"key":"e_1_2_5_11_2","unstructured":"Third MIC Cooperative Study Group. 1987. Morphologic Immunologic and Cytogenetic (MIC) working classification. Of the primary myelodysplastic syndromes and therapy related myelodysplasias and leukemias. Cancer32:1\u201310"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(85)90016-0"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(96)00350-0"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8438156"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","unstructured":"Le Beau M.M 1993. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc. Natl. Acad. Sci. USA90:5484\u20135488.","DOI":"10.1073\/pnas.90.12.5484"},{"key":"e_1_2_5_16_2","first-page":"1930","article-title":"Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid disorders","volume":"88","author":"Beau M.M.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_17_2","first-page":"370","article-title":"Myelodysplastic syndromes and acute myeloid leukaemia with 17p deletion","volume":"9","author":"Lai J.L.","year":"1995","journal-title":"An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"e_1_2_5_19_2","first-page":"1790","article-title":"The tel\u2010PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice","volume":"11","author":"Ritchie K.A.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203190"},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1182\/blood.V91.12.4419","article-title":"Fusion of huntingtin interacting protein 1 to platelet\u2010derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukaemia with t(5;7) (q33;q11.2)","volume":"91","author":"Ross T.S.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2518"},{"key":"e_1_2_5_24_2","first-page":"3592","article-title":"Fusion of H4\/D10S170 to the platelet\u2010derived growth factor receptor beta in BCR\/ABL\u2010negative myeloproliferative disorders with a t(5:10)(q33:q21)","volume":"60","author":"Kulkarni S.","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/blood.V90.11.4271","article-title":"Fusion of the platelet\u2010derived growth factor beta to a novel gene CEV in acute myelogenous leukaemia after clonal evolution","volume":"90","author":"Abe A.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_26_2","first-page":"408","article-title":"Sensitivity to Imatinib but low frequency of the TEL\/PDGFRb fusion protein in chronic myelomonocytic leukaemia","volume":"88","author":"Gumby R.H.","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_5_27_2","first-page":"67","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia","volume":"118","author":"Kroger N.","year":"2002","journal-title":"A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and marrow Transplantation (EBMT). Br. J. Haematol"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020150"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.V84.4.1243.1243","article-title":"Expression of EVI1 in myelodysplastic syndromes and other haematological malignancies without 3q26 translocations","volume":"84","author":"Russell M.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_30_2","first-page":"203","article-title":"Expression of EVI\u20101 gene in myelodysplastic syndromes","volume":"9","author":"Dreyfus F.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00031-X"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400880"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.9.3937"},{"key":"e_1_2_5_34_2","first-page":"535","article-title":"Clinical correlation of he 3q21;q26 cytogenetic anomaly","volume":"55","author":"Pintado T.","year":"1985","journal-title":"A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02472.x"},{"key":"e_1_2_5_36_2","doi-asserted-by":"crossref","unstructured":"Padua R.A.et al.1998 RAS FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10 year follow\u2010up. Leukemia12:887\u2013892.","DOI":"10.1038\/sj.leu.2401044"},{"key":"e_1_2_5_37_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V82.2.590.590","article-title":"N\u2010ras mutations are associated with poor prognosis and increased risk of leukaemia in myelodysplastic syndromes","volume":"82","author":"Paquette R.L.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_5_38_2","first-page":"561","article-title":"Ras and the myelodysplastic syndromes","volume":"45","author":"Gallagher A.","year":"1997","journal-title":"Pathol. Biol"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.56.070187.004023"},{"key":"e_1_2_5_40_2","first-page":"4682","article-title":"ras oncogenes in human cancer: a review","volume":"49","author":"Bos J.L.","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_5_41_2","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V83.6.1603.bloodjournal8361603","article-title":"Prognostic importance of mutations in the ras proto\u2010oncogenes in de novo acute myeloid leukaemia","volume":"83","author":"Neubauer A.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_42_2","first-page":"1871","article-title":"A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity","volume":"60","author":"Adjei A.A.","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3361"},{"key":"e_1_2_5_44_2","unstructured":"Feldman E.J.et al.2003. Continuous oral Lonafarnib (Sarasar) for the treatment of patients with myelodyspastic syndrome. Blood102(suppl.): abstr. 1531."},{"key":"e_1_2_5_45_2","unstructured":"Lancet J.E.et al.2003. Tipifarnib (ZARNESTRA) in previously untreated poor\u2010risk AML and MDS: interim results of a phase 2 trial. Blood102(Suppl.): abstr. 613."},{"key":"e_1_2_5_46_2","first-page":"19","article-title":"Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukaemia","volume":"88","author":"Moreno I.","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02821.x"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400770"},{"key":"e_1_2_5_49_2","first-page":"4326","article-title":"Analysis of FLT3\u2010activating mutations in 979 patients with acute myelogenous leukaemia","volume":"99","author":"Thiede C.","year":"2002","journal-title":"Association with FAB subtypes and identification of subgroups with poor prognosis. Blood"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402810"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0531"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00070-3"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3361"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.10.040192.003153"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(97)80050-7"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3272"},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90601-A"},{"key":"e_1_2_5_58_2","unstructured":"Baird P.N.et al.1997 Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp. Hematol.25:312\u2013320."},{"key":"e_1_2_5_59_2","doi-asserted-by":"crossref","unstructured":"Cilloni D.et al.2002 Quantitative assessment of WT1 expression by RealTime\u2010Q\u2010PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia16:2115\u20132121.","DOI":"10.1038\/sj.leu.2402675"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.2267.bloodjournal8862267"},{"key":"e_1_2_5_61_2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood.V89.4.1405","article-title":"Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia","volume":"89","author":"Inoue K.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_62_2","doi-asserted-by":"crossref","unstructured":"Cilloni D.et al.2003. Usefulness of quantitative assessment of Wilms tumor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. Semin. Hematol.40:37\u201341","DOI":"10.1053\/shem.2003.50040"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.503"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1322.048","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1322.048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T17:29:13Z","timestamp":1695662953000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1322.048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1196\/annals.1322.048"],"URL":"https:\/\/doi.org\/10.1196\/annals.1322.048","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}